Most breast cancer is not inherited. About 5% to 10% of all breast cancer cases result from gene mutations passed down through families, while the remaining 90% to 95% arise from genetic damage that accumulates over a person’s lifetime due to aging, hormonal factors, and environmental exposures. So genetics can play a role, but for the vast majority of people diagnosed with breast cancer, there is no single inherited gene to point to.
That said, the inherited forms of breast cancer tend to strike earlier and carry significantly higher lifetime risks. Understanding the difference between hereditary and non-hereditary breast cancer matters for anyone with a family history of the disease.
How Hereditary Breast Cancer Works
Every cell in your body contains genes that help repair damaged DNA. Two of the most important for breast cancer risk are BRCA1 and BRCA2. When these genes work normally, they produce proteins that fix DNA breaks and prevent cells from growing out of control. When you inherit a harmful change in one of these genes, that repair system is compromised, and cells are more likely to accumulate the kind of damage that leads to cancer.
These mutations follow an autosomal dominant inheritance pattern, which means you only need to inherit one changed copy (from either parent) for your risk to increase. If a parent carries a BRCA1 or BRCA2 mutation, each of their children has a 50% chance of inheriting it. The vast majority of people with these mutations inherited them rather than developing them spontaneously.
For context, the average woman born in the United States today has about a 12.9% lifetime risk of developing breast cancer, roughly 1 in 8. Women who carry a harmful BRCA1 mutation face a lifetime breast cancer risk estimated around 60% or higher, while BRCA2 carriers face a somewhat lower but still substantially elevated risk. The difference is dramatic enough that carriers often pursue aggressive screening or preventive measures.
BRCA Is Not the Only Gene That Matters
BRCA1 and BRCA2 get the most attention, but several other genes also raise breast cancer risk. These are sometimes called “moderate-risk” genes because they increase risk by a smaller margin. The three most studied are PALB2, CHEK2, and ATM.
PALB2 produces a protein that works directly with BRCA2 to repair DNA. Certain PALB2 mutations roughly quadruple a woman’s breast cancer risk compared to someone without the mutation. CHEK2 and ATM mutations generally double or triple the risk, though specific variants within each gene carry different levels of danger. One particular ATM variant has been linked to a much larger risk increase, likely because it doesn’t just disable the gene but actively interferes with the protein’s normal function.
These genes individually account for a small fraction of breast cancers, but collectively they explain a meaningful share of hereditary cases that test negative for BRCA mutations. Researchers estimate that non-BRCA gene mutations account for 1% to 12% of inherited breast cancers.
Certain Populations Carry Higher Risk
Some ethnic groups have a notably higher prevalence of BRCA mutations. Ashkenazi Jewish women are the most well-studied example. Roughly 2% to 2.5% of Ashkenazi Jewish women carry one of three specific founding mutations in BRCA1 or BRCA2, compared to an estimated 0.2% to 0.3% in the general population. About 12% of breast cancers in this population are attributable to these mutations.
Among Ashkenazi Jewish women with breast cancer, researchers found that nearly all mutation carriers either developed cancer before age 50 or had a close relative with ovarian cancer or early-onset breast cancer. The estimated lifetime risk of breast cancer by age 70 was about 60% for BRCA1 carriers and 28% for BRCA2 carriers in this group. Other populations with elevated BRCA mutation rates include Icelandic, Norwegian, and Dutch communities, each with their own founder mutations.
Men Can Carry and Be Affected by These Genes
Breast cancer in men is rare, but it does happen, and genetics plays a proportionally larger role. Men can inherit BRCA1 and BRCA2 mutations just as women can, and they pass them to their children at the same 50% rate. BRCA2 mutations in particular raise male breast cancer risk meaningfully above the general male population’s baseline, which is less than 1%.
This is important because families sometimes overlook the paternal side when thinking about breast cancer risk. A father who carries a BRCA mutation may never develop breast cancer himself but can still pass the mutation to daughters and sons alike.
What Genetic Testing Involves
Genetic testing for breast cancer risk typically starts with a blood or saliva sample. The simplest tests look only at BRCA1 and BRCA2, but most current testing uses multigene panels that analyze anywhere from 6 to over 100 genes simultaneously. These panels roughly double the detection rate of cancer-related mutations compared to testing BRCA genes alone.
There is a significant catch. Multigene panels frequently turn up what are called variants of uncertain significance: genetic changes that look unusual but haven’t been definitively linked to cancer risk. Across multiple studies, the rate of these uncertain results ranges from about 7% to as high as 88%, depending on how many genes the panel covers and the population tested. An uncertain result can create anxiety without offering clear guidance, since there’s no established way to act on it. Over time, as more data accumulates, many of these variants get reclassified as either harmless or harmful, but that process can take years.
Testing is most informative when there’s a strong signal in your family history: multiple relatives with breast or ovarian cancer, cancer diagnosed before age 50, male breast cancer, or ancestry from a high-risk population. A genetic counselor can help interpret results and put them in the context of your overall risk profile.
Options for People With High-Risk Mutations
If you test positive for a BRCA1 or BRCA2 mutation, several risk-reduction strategies are available. Enhanced screening, which typically combines mammography with breast MRI starting at a younger age than standard guidelines recommend, aims to catch cancers early when they’re most treatable.
Preventive surgery is the most effective option for reducing risk. Bilateral mastectomy reduces breast cancer risk by at least 95% in BRCA carriers. This is a major decision with lasting physical and emotional consequences, and the choice is deeply personal. Some carriers opt for increased surveillance instead, or combine surveillance with medications that lower hormonal exposure to breast tissue.
For carriers of moderate-risk gene mutations like PALB2 or CHEK2, recommendations are less standardized. Enhanced screening is common, but preventive surgery decisions depend on the specific mutation, family history, and individual circumstances.
Family History Matters Even Without a Known Mutation
Plenty of women with a strong family history of breast cancer test negative for every known mutation. This doesn’t mean genetics isn’t involved. Many breast cancers likely result from combinations of common, low-risk genetic variants that individually have a tiny effect but together nudge risk upward. Others may involve genes that haven’t been identified yet.
Having a first-degree relative (mother, sister, or daughter) with breast cancer roughly doubles your risk regardless of whether a specific mutation has been found. Having two first-degree relatives with breast cancer increases it further. Even among Ashkenazi Jewish breast cancer patients who don’t carry BRCA mutations, first-degree relatives still face a moderately elevated risk compared to the general population, suggesting other genetic or shared environmental factors at play.
The practical takeaway: a negative genetic test is reassuring but doesn’t erase the significance of a strong family history. Your overall risk picture combines genetics, family history, reproductive factors, lifestyle, and age.